Glafabra Therapeutics is considering a capital raise and is testing the waters under Regulation Crowdfunding.
Public source
Publisher name
Public post
Follow our story: https://lnkd.in/gF7ZsJdw One platform, three diseases, and a body of intellectual property built to protect all three at once. Glafabra's patent positi…
Company
Glafabra Therapeutics
Gene therapy for Fabry and other enzyme deficiencies - one dose for years long durability and patient freedom
- Industry
- Biotechnology Research
- Company size
- 2–10 employees
About Glafabra Therapeutics
Glafabra is a biotherapeutics development company focused on bringing into the clinic our Live-cel(TM) technology for cell-based gene therapy (Cb-GT). Our approach for Fabry Disease provides a 130x improvement in effectiveness for patients, when compared to the standard of care of enzyme replacement therapy. We are bringing to the clinic a therapy that is long acting. Where just one dose, can last for years, not weeks.
See moreLatest activity
Latest activity from Glafabra Therapeutics
9 signals
Capital & Finance
Glafabra Therapeutics is considering a capital raise and is testing the waters under Regulation Crowdfunding.
Legal & Regulatory
Glafabra Therapeutics is considering a capital raise and is
Capital & Finance
Glafabra Therapeutics is considering a capital raise under Regulation Crowdfunding.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
PackGene Biotech, Inc.
PackGene Biotech, Inc. announced that a new AAV gene therapy from Ultragenyx was approved by the FDA for patients with glycogen storage disease type Ia.
Legal & Regulatory
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. received a Biologics License Application (BLA) with Priority Review from the FDA for a potential one-time hereditary angioedema treatment, with a PDUFA target action date of March 10, 2027.
Legal & Regulatory
Ultragenyx
Ultragenyx received FDA approval for its first gene therapy drug substance and manufacturing facility for GSDIa.
Legal & Regulatory
Illuminare Biotechnologies
Illuminare Biotechnologies held a formal meeting with the FDA to gain clarity on its planned Phase II clinical study and its target initiation date.
Legal & Regulatory
uniQure